Chronic urticaria is a common disorder of the skin, characterised by recurrent skin wheals and angioedema. Recent reports have shown that altered diversity and composition of the gut microbiota may lead to imbalances in immune regulation, a causal factor in the occurrence of chronic urticaria. This study aimed to evaluate the efficacy of the Yimingjia® probiotic formula in the adjuvant treatment of chronic urticaria in children. We enrolled 206 children with confirmed diagnoses of chronic urticaria and randomly assigned them to the treatment (n = 104) or placebo group (n = 102). The children in each group were treated with desloratadine dry suspension, and those in the treatment group also received Yimingjia®. Clinical efficacy was evaluated at 1, 2 and 4 weeks. Clinical symptom scores did not differ significantly at weeks 1 and 2 (p > 0.05), but at 4 weeks, wheal size and attack frequency were significantly reduced in the treatment group (p = 0.049 and 0.03, respectively). The overall response rate (significant improvement + complete response) significantly differed between the treatment (80.8%) and placebo groups (62.5%) (χ2 = 4.20, p = 0.04). Adjunct therapy with Yimingjia® was safe and effective at 4 weeks in the treatment of chronic urticaria in children. The study was registered under trial number NCT03328897.

中文翻译：

---

益生菌对儿童慢性荨麻疹的辅助治疗：随机安慰剂对照试验

慢性荨麻疹是一种常见的皮肤疾病，其特征是皮肤反复出现风疹和血管性水肿。最近的报道表明，肠道菌群多样性和组成的改变可能导致免疫调节失衡，这是慢性荨麻疹发生的原因。这项研究旨在评估益明加益生菌配方在儿童慢性荨麻疹的辅助治疗中的功效。我们招募了206名确诊为慢性荨麻疹的儿童，并将他们随机分配至治疗组（n = 104）或安慰剂组（n = 102）。每组的儿童均接受去氯雷他定干混悬液治疗，治疗组中的儿童也接受了伊明加®治疗。在1、2和4周时评估临床疗效。第1周和第2周的临床症状评分无显着差异（p> 0.05），但在第4周时，治疗组的风团大小和发作频率显着降低（分别为p = 0.049和0.03）。治疗组（80.8％）和安慰剂组（62.5％）之间的总缓解率（显着改善+完全缓解）显着不同（χ2= 4.20，p = 0.04）。使用益明佳®的辅助疗法在治疗儿童慢性荨麻疹的第4周是安全有效的。该研究的注册号为NCT03328897。使用益明佳®的辅助疗法在治疗儿童慢性荨麻疹的第4周是安全有效的。该研究的注册号为NCT03328897。使用益明佳®的辅助疗法在治疗儿童慢性荨麻疹的第4周是安全有效的。该研究的注册号为NCT03328897。